• Both divisions grew simultaneously, margins remained solid and the net leverage ratio fell to 2.63x, meeting the target set at the time of the IPO one year ahead of schedule

Madrid, April 21, 2026 – Labiana, the Spanish pharmaceutical group dedicated to the development, manufacturing and commercialisation of medicines in the animal and human health sectors, listed on BME Growth, achieved revenues of €75.2 million in 2025, representing a 13.5% increase compared to the previous year. This double-digit growth was driven in a balanced way by both the animal and human health divisions, which generated revenues of €36.9 million and €38.3 million respectively, as the company announced today during its results presentation in Seville.

Beyond this increase in sales, Labiana posted a profit of €2.6 million last year, multiplying by twelve the €0.2 million profit recorded a year earlier. In addition, Adjusted EBITDA closed the year at €11.7 million, up 20.6%. Likewise, the gross margin stood at 59.5%, remaining at excellent levels despite the strong increase in volume, thanks to the productivity efficiency improvements introduced at both manufacturing plants.

According to Manuel Ramos, CEO of Labiana, “2025 was by far the best financial year in Labiana’s recent history from a financial standpoint, not only because of the sales volume but also due to the quality of this growth, which consolidates our business model. The company is growing, investing and at the same time reducing its debt, which has also allowed us in recent months to strengthen our capital structure, as reflected in the recent financing and capital increase transactions, which have been very well received by the market.”

By business area, the CDMO division (production and development of medicines for third parties) generated revenues of €47.2 million (up 4.8%), consolidating its position as a source of recurring income for the group. Meanwhile, the company’s own product portfolio was the main growth driver, with revenues increasing by 30.4% to €27.9 million, reflecting the success of the strategy focused on proprietary product development and international expansion.

In terms of investment, the company allocated approximately €4 million to the upgrading of its production facilities in order to consolidate this growth from 2026 onwards. These investments, partially financed through the final tranche of the Miralta & Blantyre loan, explain the negative free cash flow for the year and the slight increase in Net Financial Debt to €30.8 million. Even so, the Net Debt/Adjusted EBITDA ratio decreased from 3x to 2.63x, meeting the public target set for 2026 one year ahead of schedule.

By region, Spain grew by 17.9% to €22 million, consolidating the domestic market as the group’s second growth engine. The European Union excluding Spain maintained its position as the main market, accounting for 56.5% of total revenues. The rest of the world was the most dynamic area, with growth of 78.8%, driven by the international expansion of Zoleant, the group’s Turkish subsidiary, in markets such as the United Arab Emirates, Vietnam and Turkey.